Ishiko O - Search Results

1

Expression of mitotic-arrest deficiency 2 predicts the efficacy of neoadjuvant chemotherapy for locally advanced uterine cervical cancer.

Morishita M, Sumi T, Nakano Y, Teramae M, Fukuda T, Nobeyama H, Yoshida H, Matsumoto Y, Yasui T, Ishiko O. Morishita M, et al. Among authors: ishiko o. Exp Ther Med. 2012 Feb;3(2):341-346. doi: 10.3892/etm.2011.407. Epub 2011 Dec 5. Exp Ther Med. 2012. PMID: 22969893 Free PMC article.

2

Association of HPV infection with prognosis after neoadjuvant chemotherapy in advanced uterine cervical cancer.

Nobeyama H, Sumi T, Misugi F, Okamoto E, Hattori K, Matsumoto Y, Yasui T, Honda K, Iwai K, Ishiko O. Nobeyama H, et al. Among authors: ishiko o. Int J Mol Med. 2004 Jul;14(1):101-5. Int J Mol Med. 2004. PMID: 15202023

3

Expression of apoptosis-related proteins in advanced uterine cervical cancer after balloon-occluded arterial infusion chemotherapy as an indicator of the efficiency of this therapy.

Okamoto E, Sumi T, Misugi F, Nobeyama H, Hattori K, Yoshida H, Matsumoto Y, Yasui T, Honda K, Ishiko O. Okamoto E, et al. Among authors: ishiko o. Int J Mol Med. 2005 Jan;15(1):41-7. Int J Mol Med. 2005. PMID: 15583826 Clinical Trial.

4

Mitotic arrest deficiency 2 induces carcinogenesis in mucinous ovarian tumors.

Nakano Y, Sumi T, Morishita M, Fukuda T, Nobeyama H, Yoshida H, Matsumoto Y, Yasui T, Ishiko O. Nakano Y, et al. Among authors: ishiko o. Oncol Lett. 2012 Feb;3(2):281-286. doi: 10.3892/ol.2011.483. Epub 2011 Nov 15. Oncol Lett. 2012. PMID: 22740895 Free PMC article.

5

Expression of the mitotic-arrest deficiency 2 is associated with chemotherapy resistance in ovarian serous adenocarcinoma.

Nakano Y, Sumi T, Teramae M, Morishita M, Fukuda T, Terada H, Yoshida H, Matsumoto Y, Yasui T, Ishiko O. Nakano Y, et al. Among authors: ishiko o. Oncol Rep. 2012 Oct;28(4):1200-4. doi: 10.3892/or.2012.1907. Epub 2012 Jul 12. Oncol Rep. 2012. PMID: 22797604

6

Expression of survivin and matrix metalloproteinases in adenocarcinoma and squamous cell carcinoma of the uterine cervix.

Yoshida H, Sumi T, Hyun Y, Nakagawa E, Hattori K, Yasui T, Morimura M, Honda K, Nakatani T, Ishiko O. Yoshida H, et al. Among authors: ishiko o. Oncol Rep. 2003 Jan-Feb;10(1):45-9. Oncol Rep. 2003. PMID: 12469143

7

Expression of matrix metalloproteinases in human transitional cell carcinoma of the urinary bladder.

Sumi T, Yoshida H, Hyun Y, Yasui T, Matsumoto Y, Hattori K, Sugimura K, Kawashima H, Nakatani T, Ishiko O. Sumi T, et al. Among authors: ishiko o. Oncol Rep. 2003 Mar-Apr;10(2):345-9. Oncol Rep. 2003. PMID: 12579270

8

Expression of matrix metalloproteinases 7 and 2 in human renal cell carcinoma.

Sumi T, Nakatani T, Yoshida H, Hyun Y, Yasui T, Matsumoto Y, Nakagawa E, Sugimura K, Kawashima H, Ishiko O. Sumi T, et al. Among authors: ishiko o. Oncol Rep. 2003 May-Jun;10(3):567-70. Oncol Rep. 2003. PMID: 12684625

9

Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in uterine endometrial carcinoma and a correlation between expression of matrix metalloproteinase-7 and prognosis.

Misugi F, Sumi T, Okamoto E, Nobeyama H, Hattori K, Yoshida H, Matsumoto Y, Yasui T, Honda K, Ishiko O. Misugi F, et al. Among authors: ishiko o. Int J Mol Med. 2005 Oct;16(4):541-6. Int J Mol Med. 2005. PMID: 16142384

10

Vascular endothelial growth factor, matrix metalloproteinases, and cyclooxygenase-2 influence prognosis of uterine cervical cancer in young women.

Noriyuki M, Sumi T, Zhi X, Misugi F, Nobeyama H, Yoshida H, Matsumoto Y, Yasui T, Honda K, Ishiko O. Noriyuki M, et al. Among authors: ishiko o. Int J Oncol. 2007 Sep;31(3):531-6. Int J Oncol. 2007. PMID: 17671679

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

191 results

Search Page

Filters